

Announcement no. 15/2007

To OMX The Nordic Exchange, Copenhagen, and the press

Vedbæk, 24 September 2007

Exiqon A/S increases its share capital in connection with exercise of warrants

Exiqon A/S has today 24 September, 2007, completed and filed an increase of its share capital by DKK 132,312, nominal value, with the Danish Commerce and Companies Agency as a result of employees exercising warrants. The registered share capital subsequently amounts to DKK 24,406,802, nominal value, divided into 24,406,802 shares of DKK 1.00, nominal value, each.

The new shares are in accordance with the terms of the warrants exercised subscribed for without any pre-emption rights for the existing shareholders of the company, and the subscription price was DKK 9.50 per share of DKK 1.00, nominal value, each.

The new shares shall carry a right to any dividend for the financial year 2007 from the time of registration of the capital increase.

Following the exercise the number of outstanding warrants is 2,239,494.

For additional information please contact

Lars Kongsbak, CEO, tel. +45 4566 0888 or +45 4090 2101

Hans Henrik Chrois Christensen, CFO, tel. +45 4565 0953 or +45 4090 2131

About Exiqon

Exiqon is a leading supplier of high-value gene expression analysis products for the life sciences, research and drug discovery industries. Exiqon's rapidly growing product offerings integrate innovative chemistries with web-based software tools to help scientists achieve rapid and reliable results. Exiqon markets its products directly on www.exiqon.com or through distributors in the EU and Asia, as well as through its international sales force. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark and in Boston, USA. Please visit our web-site at www.exiqon.com.